Research Progress of Prostate Cancer Stem Cell Inhibitors

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (20 September 2024) | Viewed by 468

Special Issue Editor

Special Issue Information

Dear Colleagues,

Prostate cancer (PCa) is the second leading cause of mortality and morbidity among men worldwide. The standard care of therapy for PCa comprises chemotherapy, radiation therapy, brachytherapy, secondary hormonal and targeted therapies, and surgery, although a multitherapy approach is usually preferred in many patients depending on the disease stage. Nevertheless, castration-resistant prostate cancer (CRPC) develops due to the presence of a subpopulation of cancer stem cells (CSCs) within the tumor bulk. This instigates the development of novel therapeutic approaches using targeted therapies, including prostate cancer stem cell (PCSC) inhibitors.Targeting PCSC-related signaling pathways include inhibitors against the Hedgehog (Hh) pathways, Wnt signaling, Notch, NF-κB, and PI3K/AKT/mTOR, among other pathways. This approach in the management of PCa is the hub for “personalized medicine” in the 21st century. It is an area of great interest to physicians and researchers working in the scientific field—in particular, molecular pathologists and hematology oncologists.This Special Issue focuses on research and experiences related to PCSC targeted therapies. It will include research papers, reviews, and case reports that cover the identification of novel therapeutic targets, with a focus on the prospects for improving personalized cancer care using new technologies to enhance cancer patient diagnoses, management, and outcomes.

In this issue, we invite researchers in genitourinary pathology, hematology oncology, and other fields of cancer research to submit high-quality empirical papers or reviews related to the issues in this research area. 

Dr. Hisham Bahmad
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • cancer stem cells
  • inhibitors
  • biomarkers
  • therapeutic target
  • personalized medicine
  • targeted therapy
  • molecular signatures
  • diagnosis
  • prognosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop